Processa Pharmaceuticals, Inc. 8-K

What Happened
Processa Pharmaceuticals, Inc. (PCSA) filed an 8‑K on January 7, 2026, reporting that on January 6, 2026 it received written notification from the Nasdaq Listing Qualifications Staff that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The notification states the matter is now closed.

Key Details

• Notification date: January 6, 2026.
• Filing date: Form 8‑K filed January 7, 2026.
• Requirement satisfied: $1.00 minimum closing bid price under Nasdaq Listing Rule 5550(a)(2).
• Outcome: Nasdaq confirmed compliance and closed the matter (no further remedial action noted).

Why It Matters
Regaining compliance avoids potential delisting for Processa and preserves its Nasdaq Capital Market listing, which supports market liquidity, investor access, and the company’s ability to raise capital. This 8‑K does not report earnings, officer changes, or new financial results—only the Nasdaq compliance update. Investors should view this as a technical regulatory milestone rather than an operational or financial performance disclosure.